Syndecan-1 and E-Cadherin Expression in Canine Cutaneous Squamous Cell Carcinoma

Overview

Journal Vet Sci

Publisher MDPI

Specialty Veterinary Medicine

Date 2024 Dec 27

PMID 39728992

Authors

Rita Files

Claudia Cardoso

Justina Prada

Filipe Silva

Isabel Pires

Affiliations

Soon will be listed here.

Abstract

Cutaneous squamous cell carcinoma (CSCC) in dogs is a locally invasive tumor that typically occurs in areas of poorly pigmented skin due to sun exposure. Identifying new biomarkers, such as syndecan-1 (CD138) and E-cadherin, is fundamental for tumor diagnosis and prognosis. Dysregulation of syndecan-1, expressed in epithelial tissue, fibroblasts, and plasma cells, is associated with poor prognosis in several types of cancer. Similarly, E-cadherin, which plays a crucial role in cell adhesion and epithelial functionality, is also linked to adverse outcomes. This study evaluated the expression of syndecan-1 and E-cadherin in 47 cases of canine cutaneous squamous cell carcinoma. The results showed that the intensity of syndecan-1 decreased with increasing tumor aggressiveness, and its presence in the stroma was significantly associated with tumor grade. E-cadherin also demonstrated a decrease in intensity with increasing malignancy. However, the association between syndecan-1 and E-cadherin was not statistically significant. E-cadherin reduction and stromal syndecan-1 positivity seem to be associated with tumor aggressiveness in canine cutaneous squamous cell carcinoma. Further studies are needed to explore their roles in tumor progression.

References

Fundyler O, Khanna M, Smoller B . Metalloproteinase-2 expression correlates with aggressiveness of cutaneous squamous cell carcinomas. Mod Pathol. 2004; 17(5):496-502. DOI: 10.1038/modpathol.3800066. View

Loussouarn D, Campion L, Sagan C, Frenel J, Dravet F, Classe J . Prognostic impact of syndecan-1 expression in invasive ductal breast carcinomas. Br J Cancer. 2008; 98(12):1993-8. PMC: 2441962. DOI: 10.1038/sj.bjc.6604400. View

Mestrinho L . Current Status and Future Perspectives in Canine Oral Squamous Cell Carcinoma. Vet Pathol. 2018; 55(2):200-201. DOI: 10.1177/0300985817732114. View

Guilford P . E-cadherin downregulation in cancer: fuel on the fire?. Mol Med Today. 1999; 5(4):172-7. DOI: 10.1016/s1357-4310(99)01461-6. View

Shimokawa M, Haraguchi M, Kobayashi W, Higashi Y, Matsushita S, Kawai K . The transcription factor Snail expressed in cutaneous squamous cell carcinoma induces epithelial-mesenchymal transition and down-regulates COX-2. Biochem Biophys Res Commun. 2012; 430(3):1078-82. DOI: 10.1016/j.bbrc.2012.12.035. View

Pires I, Alves A, Queiroga F, Silva F, Lopes C . Regression of canine cutaneous histiocytoma: reduced proliferation or increased apoptosis?. Anticancer Res. 2013; 33(4):1397-400. View

Wang S, Cao K, He Q, Yin Z, Zhou J . miR-199a-5p induces cell invasion by suppressing E-cadherin expression in cutaneous squamous cell carcinoma. Oncol Lett. 2016; 12(1):97-101. PMC: 4906706. DOI: 10.3892/ol.2016.4602. View

Nunez A, Siegal G, Reddy V, Wei S . CD138 (syndecan-1) expression in bone-forming tumors. Am J Clin Pathol. 2012; 137(3):423-8. DOI: 10.1309/AJCP6V4YPFBOCYXG. View

Ortloff A, Bustamante F, Molina L, Ojeda J, Figueroa C, Ehrenfeld P . Kallikrein-related Peptidase 5 (KLK5) Expression and Distribution in Canine Cutaneous Squamous Cell Carcinoma. J Comp Pathol. 2020; 174:113-119. DOI: 10.1016/j.jcpa.2019.11.009. View

10.

Arslan Solmaz O . The role of syndecan-1 during endometrial carcinoma progression. J Cancer Res Ther. 2020; 15(6):1265-1269. DOI: 10.4103/jcrt.JCRT_364_17. View

11.

Celia-Terrassa T, Kang Y . How important is EMT for cancer metastasis?. PLoS Biol. 2024; 22(2):e3002487. PMC: 10849258. DOI: 10.1371/journal.pbio.3002487. View

12.

Bellizzi A . An Algorithmic Immunohistochemical Approach to Define Tumor Type and Assign Site of Origin. Adv Anat Pathol. 2020; 27(3):114-163. PMC: 7700753. DOI: 10.1097/PAP.0000000000000256. View

13.

Wong S, Fang C, Chuah L, Leong C, Ching Ngai S . E-cadherin: Its dysregulation in carcinogenesis and clinical implications. Crit Rev Oncol Hematol. 2017; 121:11-22. DOI: 10.1016/j.critrevonc.2017.11.010. View

14.

Lo Muzio L, Pannone G, Santarelli A, Bambini F, Mascitti M, Rubini C . Is expression of p120ctn in oral squamous cell carcinomas a prognostic factor?. Oral Surg Oral Med Oral Pathol Oral Radiol. 2013; 115(6):789-98. DOI: 10.1016/j.oooo.2013.03.006. View

15.

Szatmari T, Otvos R, Hjerpe A, Dobra K . Syndecan-1 in Cancer: Implications for Cell Signaling, Differentiation, and Prognostication. Dis Markers. 2015; 2015:796052. PMC: 4569789. DOI: 10.1155/2015/796052. View

16.

Bromfield J, Zaugg J, Straw R, Cathie J, Krueger A, Sinha D . Characterization of the skin microbiome in normal and cutaneous squamous cell carcinoma affected cats and dogs. mSphere. 2024; 9(4):e0055523. PMC: 11036808. DOI: 10.1128/msphere.00555-23. View

17.

Zhu Y, Yu F, Tan Y, Yuan H, Hu F . Strategies of targeting pathological stroma for enhanced antitumor therapies. Pharmacol Res. 2019; 148:104401. DOI: 10.1016/j.phrs.2019.104401. View

18.

Bruser L, Bogdan S . Adherens Junctions on the Move-Membrane Trafficking of E-Cadherin. Cold Spring Harb Perspect Biol. 2017; 9(3). PMC: 5334258. DOI: 10.1101/cshperspect.a029140. View

19.

Diede C, Walker T, Carr D, Shahwan K . Grading differentiation in cutaneous squamous cell carcinoma: a review of the literature. Arch Dermatol Res. 2024; 316(7):434. DOI: 10.1007/s00403-024-03184-w. View

20.

Mathe M, Suba Z, Nemeth Z, Tatrai P, Fule T, Borgulya G . Stromal syndecan-1 expression is an adverse prognostic factor in oral carcinomas. Oral Oncol. 2005; 42(5):493-500. DOI: 10.1016/j.oraloncology.2005.10.003. View